Clay B. Siegall is a renowned scientist who is focused on conducting research in cancer. He currently serves as Seattle Genetics’s CEO and president. The pharmaceutical company was created in 1998, and Siegall was its co-founder. Siegall has been focused on conducting research on different cancer therapies. Seattle Genetics was founded to carry out extensive research, focus on scientific innovation, and develop new drugs. The firm has been striving to come up with an excellent cure that can assist individuals who have cancer. Clay has helped the company in discovering unique antibody-drug conjugates (ADCs). Seattle Genetics developed its first ADC that was known as ADCETRIS®, and it was approved by the FDA in 2011. The company later worked with closely Takeda Pharmaceutical Company to assist in making ADCETRIS an international brand. The drug has currently been accepted in 65 countries. Researchers at Seattle Genetics have been striving to develop ADCs that can be used in curing cancer.
Dr. Siegall has ensured that Seattle Genetics is offered various strategic licenses that allow it to conduct the manufacture and supply of ADC Technology across the globe. Some of the drugs that are sold by his company include GlaxoSmithKline, Genentech, Pfizer, and AbbVie. The company has managed to raise over $350 million from the products. The technology that has been established by the company has currently been used in the formation of more than 20 ADC that are it manufactured internally and externally by working with other pharmaceutical companies. Clay Siegall has come up with outstanding strategies that Seattle Genetics uses in raising capital. The company has managed to secure more than $1.2 billion from both private and public funding. It conducted it first public offering plan in 2001.
Clay B. Siegall had worked for different pharmaceutical corporations before he founded Seattle Genetics. He was once a researcher at the Bristol-Myers Squibb Pharmaceutical Research Institute and served it as from 1991 to 1997. Siegall was also hired by the National Cancer Institute in 1988. The organization was his first employer. The scientist has had an opportunity to serve as a board member of various pharmaceutical corporations, and they include Ultragenyx Pharmaceutical, Washington Roundtable, and BioPharmaceutica. Clay currently has more than 15 patents and has written approximately 70 publications.